ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2019
Last Updated on 02 May 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Rifaximin 550 mg tablet as add-on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy.

Subsidy status
Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

Rifaximin for reducing overt hepatic encephalopathy (2 May 2019) Rifaximin Plain English Summary (2 May 2019)